Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors

被引：0

作者：

Dumbrava, Ecaterina Elena

Cecchini, Michael

Zugazagoitia, Jon

Lopez, Juanita Suzanne

Jager, Dirk

Oliva, Marc

Ochsenreither, Sebastian

Gambardella, Valentina

Chung, Ki Y.

Longo, Federico

Razak, Albiruni Ryan Abdul

Wermke, Martin

Evans, T. R. Jeffry

Cook, Natalie

Chenard-Poirier, Maxime

Pencheva, Radost

Schaer, David

Wagener, Thomas

Wagner, Andrea

Papadopoulos, Kyriakos P.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Hosp Univ 12 Octubre, Madrid, Spain

[4] Royal Marsden NHS Trust, Sutton, Surrey, England

[5] NCT Heidelberg, Heidelberg, Germany

[6] Lhosp & Inst Invest Biomed Bellvitge IDIBELL, ICO, Barcelona, Spain

[7] Charite Univ Med Berlin, Berlin, Germany

[8] INCLIVA Biomed Res Inst, Valencia, Spain

[9] Prisma Hlth Canc Inst, Greenville, SC USA

[10] Hosp Univ Ramo y Cajal, Madrid, Spain

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Tech Univ Dresden, Fac Med, NCT UCC Early Clin Trial Unit, Dresden, Germany

[13] Univ Glasgow, Glasgow, Lanark, Scotland

[14] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[15] Univ Manchester, Manchester, Lancs, England

[16] Univ Laval, CHU Quebec, Quebec City, PQ, Canada

[17] Bayer PLC, Reading, Berks, England

[18] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA

[19] Bayer AG, Berlin, Germany

[20] START San Antonio, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2502

引用

页数：1

共 50 条

[1] Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964
Papadopoulos, Kyriakos
Cecchini, Michael
Lopez, Juanita S.
Jager, Dirk
Chung, Ki Young
Platten, Michael
Prinz, Florian
Ishii, Yuko
Schaer, David
Gutcher, Ilona
Leder, Gabriele
Pencheva, Radost
Wagener, Thomas
Scheerans, Christian
Zieschang, Carsten
Wagner, Andrea
Stamatelos, Spyros
Dumbrava, Ecaterina
CANCER RESEARCH, 2023, 83 (08)
[2] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elena Elez
Carlos Gomez-Roca
Arturo Soto Matos-Pita
Guillem Argiles
Thibaud Valentin
Cinthya Coronado
Jorge Iglesias
Teresa Macarulla
Sarah Betrian
Salvador Fudio
Katrin Zaragoza
Josep Tabernero
Jean-Pierre Delord
Investigational New Drugs, 2019, 37 : 674 - 683
[3] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elez, Elena
Gomez-Roca, Carlos
Soto Matos-Pita, Arturo
Argiles, Guillem
Valentin, Thibaud
Coronado, Cinthya
Iglesias, Jorge
Macarulla, Teresa
Betrian, Sarah
Fudio, Salvador
Zaragoza, Katrin
Tabernero, Josep
Delord, Jean-Pierre
INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
[4] RESULTS OF A FIRST-IN-HUMAN PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN ADVANCED SOLID TUMORS
Shaw, A. T.
Camidge, D. R.
Felip, E.
Sharma, S.
Tan, D. S. W.
Kim, D.
De Pas, T.
Vansteenkiste, J. F.
Santoro, A.
Liu, G.
Goldwasser, M.
Dai, D.
Boral, A. L.
Mehra, R.
ANNALS OF ONCOLOGY, 2012, 23 : 153 - 153
[5] A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Doi, Toshihiko
Takahashi, Shunji
Aoki, Daisuke
Yonemori, Kan
Hara, Hiroki
Hasegawa, Kosei
Takehara, Kazuhiro
Harano, Kenichi
Yunokawa, Mayu
Nomura, Hiroyuki
Shimoi, Tatsunori
Horie, Koji
Ogasawara, Aiko
Okame, Shinichi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (06) : 605 - 616
[6] A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
Tabernero, Josep
Dirix, Luc
Schoffski, Patrick
Cervantes, Andres
Antonio Lopez-Martin, Jose
Capdevila, Jaume
van Beijsterveldt, Ludy
Platero, Suso
Hall, Brett
Yuan, Zhilong
Knoblauch, Roland
Zhuang, Sen Hong
CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6313 - 6321
[7] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
Price, T. J.
Prenen, H.
Lugowska, I.
Falchook, G. S.
Monzon, J. G.
Arkenau, H. T.
Chawla, S. P.
Hui, M. N.
Kuboki, Y.
Dziadziuszko, R.
Ozawa, Y.
Fernandez, M. E. Elez
Lima, C. S. P. Rocha
Subbiah, V.
Tan, D. S. W.
Wang, K.
Hindoyan, A.
Shi, W.
Kistler, M.
Sadraei, N. Hashemi
ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
[8] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
Razak, Albiruni R. Abdul
Mau-Soerensen, Morten
Gabrail, Nashat Y.
Gerecitano, John F.
Shields, Anthony F.
Unger, Thaddeus J.
Saint-Martin, Jean R.
Carlson, Robert
Landesman, Yosef
McCauley, Dilara
Rashal, Tami
Lassen, Ulrik
Kim, Richard
Stayner, Lee-Anne
Mirza, Mansoor R.
Kauffman, Michael
Shacham, Sharon
Mahipal, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +
[9] A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results
Siu, Lillian L.
Yap, Timothy A.
Genta, Sofia
Pennock, Gregory
Hicking, Christine
You, Xiaoli
Mukker, Jatinder K.
Locatelli, Giuseppe
Tolcher, Anthony W.
CANCER RESEARCH, 2023, 83 (08)
[10] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
Brunetto, Andre T.
Ang, Joo Ern
Lal, Rohit
Olmos, David
Molife, L. Rhoda
Kristeleit, Rebecca
Parker, Ann
Casamayor, Isabel
Olaleye, Muyibat
Mais, Anna
Hauns, Bernhard
Strobel, Vera
Hentsch, Bernd
de Bono, Johann S.
CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504

← 1 2 3 4 5 →